OCUL
Closed
Ocular Therapeutix Inc
9.1
-0.2 (-2.16%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 9.28
Day's Range: 9.05 - 9.42
Send
sign up or login to leave a comment!
When Written:
5.16
Ocular Therapeutix Inc is a biopharmaceutical company that focuses on the development and commercialization of innovative therapies for diseases and conditions of the eye. The company is headquartered in Bedford, Massachusetts, and was founded in 2006.
Ocular Therapeutix's lead product candidate is DEXTENZA, which is a sustained-release intracanalicular insert that is designed to deliver dexamethasone to the ocular surface for up to 30 days following a single administration. DEXTENZA is currently approved by the U.S. Food and Drug Administration (FDA) for the treatment of ocular pain following ophthalmic surgery.
In addition to DEXTENZA, Ocular Therapeutix is also developing other product candidates, including OTX-TIC, which is a sustained-release intracameral implant for the treatment of glaucoma and ocular hypertension, and OTX-CSI, which is a combination product that combines a sustained-release intracameral implant with a topical corticosteroid for the treatment of inflammation and pain following cataract surgery.
Ocular Therapeutix has partnerships with several companies, including Regeneron Pharmaceuticals, Inc. and Paragon BioTeck, Inc., to develop and commercialize its product candidates. The company is publicly traded on the NASDAQ stock exchange under the ticker symbol OCUL.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Ocular Therapeutix's lead product candidate is DEXTENZA, which is a sustained-release intracanalicular insert that is designed to deliver dexamethasone to the ocular surface for up to 30 days following a single administration. DEXTENZA is currently approved by the U.S. Food and Drug Administration (FDA) for the treatment of ocular pain following ophthalmic surgery.
In addition to DEXTENZA, Ocular Therapeutix is also developing other product candidates, including OTX-TIC, which is a sustained-release intracameral implant for the treatment of glaucoma and ocular hypertension, and OTX-CSI, which is a combination product that combines a sustained-release intracameral implant with a topical corticosteroid for the treatment of inflammation and pain following cataract surgery.
Ocular Therapeutix has partnerships with several companies, including Regeneron Pharmaceuticals, Inc. and Paragon BioTeck, Inc., to develop and commercialize its product candidates. The company is publicly traded on the NASDAQ stock exchange under the ticker symbol OCUL.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!
When Written:
5.16
Ocular Therapeutix Inc. is a biopharmaceutical company that develops and commercializes therapies for diseases and conditions of the eye. The company's lead product is DEXTENZA, a corticosteroid implant used to treat postoperative ocular inflammation and pain. Other products in development include OTX-TIC, a sustained-release travoprost implant for the treatment of glaucoma and ocular hypertension, and OTX-CSI, a combination product for the treatment of allergic conjunctivitis. Ocular Therapeutix was founded in 2006 and is headquartered in Bedford, Massachusetts.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!